NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Oragenics, Inc. (OGEN) Stock Analysis

Oragenics, Inc. (OGEN) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

OGEN

$0.51

+$0.01 (+2.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OGEN with… →

OGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$0.50
Previous Close
$0.50
Day's Range
0.50–0.52
52-Week Range
0.48–1.45
Volume
8.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$2.30M
P/E Ratio
0.52
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
−8.96
EPS (ttm)Profit attributable to each share over the last twelve months.
0.98
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$9.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.51M
1-Year Return
−51.89%
Dividend and dates
Avg Volume
33.80K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−34.62%
2025−92.97%
2024−93.43%
2023−14.70%
2022−75.56%
2021+0.00%
2020−13.46%
2019−39.53%
2018−62.61%
2017−57.41%
2016 (partial year)−28.00%

As of September 4, 2026.

OGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$9.84M—
2024$0.00−$10.57M—
2023$0.00−$20.66M—
2022$0.00−$14.29M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$9.36M−$9.84M—
2024$0.00—−$10.56M−$10.57M—
2023$0.00—−$20.90M−$20.66M—
2022$0.00—−$14.42M−$14.29M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OGEN Valuation vs Biotechnology Median

Median of 656 stocks
MetricOGENBiotechnology medianvs median
P/E0.5212.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Oragenics, Inc. (OGEN) at $2.30M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 3 employees.

Over the past 52 weeks the price has ranged from $0.48 to $1.45. The most recent close on file for OGEN is $0.51, dated September 4, 2026. That is +$0.01 (+2.00%) against the previous close. The latest close sits 6.25% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $9.84M. Profit margin runs at 0%. Trailing earnings per share are 0.98.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.52. That is 0 times the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads −8.96. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −51.89%. Across 10 years the annualized return works out at −63.53%. The reported beta is 1.25. Annualized volatility over the trailing 10 years is 126.94%.

Growth & Income

No dividend is on file for OGEN.

2026 is still running; the price is −34.62% year to date. Across the complete calendar years on file, 2021 returned 0.00% and 2024 returned −93.43%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Oragenics, Inc. (OGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Oragenics, Inc. OGEN $2.30M 0.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Oragenics, Inc. trades at a P/E of 0.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Oragenics, Inc.

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Visit website →